Sna-60-367-10
| Internal ID | ebf30a92-3621-44ea-8efd-0e1e2a84f097 |
| Taxonomy | Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides |
| IUPAC Name | 5-[[5-amino-1-[[10-(3-amino-3-oxopropyl)-4-butan-2-yl-22-(2-carboxyethyl)-25-(1-hydroxyethyl)-7-[(4-hydroxyphenyl)methyl]-3,6,9,12,18,21,24,27-octaoxo-19-propyl-2-oxa-5,8,11,17,20,23,26-heptazatricyclo[28.2.2.013,17]tetratriaconta-1(33),30(34),31-trien-28-yl]amino]-1-oxopentan-2-yl]amino]-4-[(3-hydroxy-14-methylhexadecanoyl)amino]-5-oxopentanoic acid |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C75H116N12O20/c1-7-20-56-74(105)87-40-19-24-59(87)72(103)80-54(33-36-60(77)91)69(100)84-57(41-47-25-29-49(89)30-26-47)70(101)85-64(45(5)9-3)75(106)107-51-31-27-48(28-32-51)42-58(71(102)86-65(46(6)88)73(104)81-55(68(99)82-56)35-38-63(95)96)83-66(97)52(23-18-39-76)79-67(98)53(34-37-62(93)94)78-61(92)43-50(90)22-17-15-13-11-10-12-14-16-21-44(4)8-2/h25-32,44-46,50,52-59,64-65,88-90H,7-24,33-43,76H2,1-6H3,(H2,77,91)(H,78,92)(H,79,98)(H,80,103)(H,81,104)(H,82,99)(H,83,97)(H,84,100)(H,85,101)(H,86,102)(H,93,94)(H,95,96) |
| InChI Key | OXJXGUNLJLKAGJ-UHFFFAOYSA-N |
| Popularity | 0 references in papers |
| Molecular Formula | C75H116N12O20 |
| Molecular Weight | 1505.80 g/mol |
| Exact Mass | 1504.84288414 g/mol |
| Topological Polar Surface Area (TPSA) | 513.00 Ų |
| XlogP | 3.70 |
| Atomic LogP (AlogP) | 2.11 |
| H-Bond Acceptor | 19 |
| H-Bond Donor | 16 |
| Rotatable Bonds | 38 |
| RefChem:183459 |
| 4-((4-Amino-1-((4-(butan-2-yl)-22-(2-carboxyethyl)-6,9,12,21,24,27-hexahydroxy-10-(2-(C-hydroxycarbonimidoyl)ethyl)-25-(1-hydroxyethyl)-7-((4-hydroxyphenyl)methyl)-3,18-dioxo-19-propyl-2-oxa-5,8,11,17,20,23,26-heptaazatricyclo(28.2.2.0,)tetratriaconta-1(32),5,8,11,20,23,26,30,33-nonaen-28-yl)-C-hydroxycarbonimidoyl)butyl)-C-hydroxycarbonimidoyl)-4-((1,3-dihydroxy-14-methylhexadecylidene)amino)butanoate |
| 4-[(4-Amino-1-{[4-(butan-2-yl)-22-(2-carboxyethyl)-6,9,12,21,24,27-hexahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-25-(1-hydroxyethyl)-7-[(4-hydroxyphenyl)methyl]-3,18-dioxo-19-propyl-2-oxa-5,8,11,17,20,23,26-heptaazatricyclo[28.2.2.0,]tetratriaconta-1(32),5,8,11,20,23,26,30,33-nonaen-28-yl]-C-hydroxycarbonimidoyl}butyl)-C-hydroxycarbonimidoyl]-4-[(1,3-dihydroxy-14-methylhexadecylidene)amino]butanoate |
| 5-((5-amino-1-((10-(3-amino-3-oxopropyl)-4-butan-2-yl-22-(2-carboxyethyl)-25-(1-hydroxyethyl)-7-((4-hydroxyphenyl)methyl)-3,6,9,12,18,21,24,27-octaoxo-19-propyl-2-oxa-5,8,11,17,20,23,26-heptazatricyclo(28.2.2.013,17)tetratriaconta-1(33),30(34),31-trien-28-yl)amino)-1-oxopentan-2-yl)amino)-4-((3-hydroxy-14-methylhexadecanoyl)amino)-5-oxopentanoic acid |
| 5-[[5-amino-1-[[10-(3-amino-3-oxopropyl)-4-butan-2-yl-22-(2-carboxyethyl)-25-(1-hydroxyethyl)-7-[(4-hydroxyphenyl)methyl]-3,6,9,12,18,21,24,27-octaoxo-19-propyl-2-oxa-5,8,11,17,20,23,26-heptazatricyclo[28.2.2.013,17]tetratriaconta-1(33),30(34),31-trien-28-yl]amino]-1-oxopentan-2-yl]amino]-4-[(3-hydroxy-14-methylhexadecanoyl)amino]-5-oxopentanoic acid |
| CHEBI:224331 |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | - | 0.4857 | 48.57% |
| Caco-2 | - | 0.8642 | 86.42% |
| Blood Brain Barrier | - | 0.9250 | 92.50% |
| Human oral bioavailability | - | 0.6286 | 62.86% |
| Subcellular localzation | Lysosomes | 0.4960 | 49.60% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.8298 | 82.98% |
| OATP1B3 inhibitior | + | 0.9267 | 92.67% |
| MATE1 inhibitior | - | 0.8400 | 84.00% |
| OCT2 inhibitior | - | 0.9000 | 90.00% |
| BSEP inhibitior | + | 0.9483 | 94.83% |
| P-glycoprotein inhibitior | + | 0.7419 | 74.19% |
| P-glycoprotein substrate | + | 0.8842 | 88.42% |
| CYP3A4 substrate | + | 0.7489 | 74.89% |
| CYP2C9 substrate | - | 0.5968 | 59.68% |
| CYP2D6 substrate | - | 0.7892 | 78.92% |
| CYP3A4 inhibition | - | 0.7396 | 73.96% |
| CYP2C9 inhibition | - | 0.9199 | 91.99% |
| CYP2C19 inhibition | - | 0.8872 | 88.72% |
| CYP2D6 inhibition | - | 0.8267 | 82.67% |
| CYP1A2 inhibition | - | 0.9556 | 95.56% |
| CYP2C8 inhibition | + | 0.8210 | 82.10% |
| CYP inhibitory promiscuity | - | 0.9318 | 93.18% |
| UGT catelyzed | + | 0.6000 | 60.00% |
| Carcinogenicity (binary) | - | 0.8700 | 87.00% |
| Carcinogenicity (trinary) | Non-required | 0.5920 | 59.20% |
| Eye corrosion | - | 0.9898 | 98.98% |
| Eye irritation | - | 0.8957 | 89.57% |
| Skin irritation | - | 0.7910 | 79.10% |
| Skin corrosion | - | 0.9358 | 93.58% |
| Ames mutagenesis | - | 0.6637 | 66.37% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.7225 | 72.25% |
| Micronuclear | + | 0.8700 | 87.00% |
| Hepatotoxicity | - | 0.5250 | 52.50% |
| skin sensitisation | - | 0.8890 | 88.90% |
| Respiratory toxicity | + | 0.8111 | 81.11% |
| Reproductive toxicity | + | 0.9333 | 93.33% |
| Mitochondrial toxicity | + | 0.9250 | 92.50% |
| Nephrotoxicity | + | 0.6378 | 63.78% |
| Acute Oral Toxicity (c) | III | 0.5685 | 56.85% |
| Estrogen receptor binding | + | 0.6099 | 60.99% |
| Androgen receptor binding | + | 0.7372 | 73.72% |
| Thyroid receptor binding | + | 0.6650 | 66.50% |
| Glucocorticoid receptor binding | + | 0.7760 | 77.60% |
| Aromatase binding | + | 0.7487 | 74.87% |
| PPAR gamma | + | 0.7515 | 75.15% |
| Honey bee toxicity | - | 0.6668 | 66.68% |
| Biodegradation | - | 0.8500 | 85.00% |
| Crustacea aquatic toxicity | + | 0.5400 | 54.00% |
| Fish aquatic toxicity | + | 0.9430 | 94.30% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL2581 | P07339 | Cathepsin D | 99.97% | 98.95% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 99.51% | 96.09% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 99.25% | 94.45% |
| CHEMBL3837 | P07711 | Cathepsin L | 98.53% | 96.61% |
| CHEMBL2069156 | Q14145 | Kelch-like ECH-associated protein 1 | 98.41% | 82.38% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 98.31% | 91.11% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 97.84% | 99.17% |
| CHEMBL236 | P41143 | Delta opioid receptor | 96.76% | 99.35% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 96.51% | 90.71% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 96.10% | 93.00% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 95.93% | 97.09% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 95.66% | 90.08% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 95.18% | 95.89% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 95.12% | 94.66% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 94.17% | 98.05% |
| CHEMBL1907594 | P30926 | Neuronal acetylcholine receptor; alpha3/beta4 | 94.15% | 97.23% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 92.77% | 93.56% |
| CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 92.54% | 85.14% |
| CHEMBL220 | P22303 | Acetylcholinesterase | 91.67% | 94.45% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 91.55% | 95.50% |
| CHEMBL1801 | P00747 | Plasminogen | 91.16% | 92.44% |
| CHEMBL1293287 | P14735 | Insulin-degrading enzyme | 91.02% | 88.10% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 91.00% | 97.64% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 90.94% | 95.00% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 90.70% | 100.00% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 90.58% | 96.90% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 89.89% | 100.00% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 89.62% | 95.56% |
| CHEMBL1255126 | O15151 | Protein Mdm4 | 89.44% | 90.20% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 89.07% | 95.89% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 89.05% | 97.14% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 88.76% | 96.47% |
| CHEMBL4777 | P25929 | Neuropeptide Y receptor type 1 | 88.23% | 96.67% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 88.17% | 96.11% |
| CHEMBL4018 | P49146 | Neuropeptide Y receptor type 2 | 87.63% | 98.94% |
| CHEMBL2413 | P32246 | C-C chemokine receptor type 1 | 86.84% | 89.50% |
| CHEMBL5852 | Q96P65 | Pyroglutamylated RFamide peptide receptor | 85.68% | 85.00% |
| CHEMBL1075317 | P61964 | WD repeat-containing protein 5 | 85.23% | 96.33% |
| CHEMBL5203 | P33316 | dUTP pyrophosphatase | 85.12% | 99.18% |
| CHEMBL2001 | Q9H244 | Purinergic receptor P2Y12 | 83.78% | 96.00% |
| CHEMBL1907591 | P30926 | Neuronal acetylcholine receptor; alpha4/beta4 | 83.62% | 100.00% |
| CHEMBL2243 | O00519 | Anandamide amidohydrolase | 83.61% | 97.53% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 83.53% | 94.75% |
| CHEMBL340 | P08684 | Cytochrome P450 3A4 | 83.43% | 91.19% |
| CHEMBL1902 | P62942 | FK506-binding protein 1A | 82.57% | 97.05% |
| CHEMBL4330 | Q9NS75 | Cysteinyl leukotriene receptor 2 | 82.47% | 98.00% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 82.42% | 90.17% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 82.22% | 92.88% |
| CHEMBL1795139 | Q8IU80 | Transmembrane protease serine 6 | 82.00% | 98.33% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 81.89% | 100.00% |
| CHEMBL4633 | P22001 | Voltage-gated potassium channel subunit Kv1.3 | 81.56% | 100.00% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 81.10% | 97.25% |
| CHEMBL4101 | P17612 | cAMP-dependent protein kinase alpha-catalytic subunit | 81.01% | 82.86% |
| CHEMBL4026 | P40763 | Signal transducer and activator of transcription 3 | 80.46% | 82.69% |
| CHEMBL3524 | P56524 | Histone deacetylase 4 | 80.43% | 92.97% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 139589223 |
| LOTUS | LTS0273806 |
| wikiData | Q105202750 |